ProCE Banner Activity

Bridging the Diagnostic Gaps in HER2-Low/-Ultralow Breast Cancer Pathology Reporting

Clinical Thought

Expert faculty recently addressed FAQs regarding the most challenging issues with HER2 scoring, specifically HER2-low/-ultralow, in metastatic breast cancer. This commentary summarizes some of the most insightful questions and their responses.

Released: May 13, 2025

Expiration: November 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Savitri Krishnamurthy, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Liza Quintana, MD, has no relevant financial relationships to disclose.

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle, BioNTech, Blueprint Medicines, Bristol Myers Squibb/SystImmune, Circle, Cullinan, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Summit Therapeutics, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/SystImmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer/Seattle Genetics.